Atlas Trials

Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes

Clinical trial NCT07046273 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07046273
Sponsor
Shandong New Time Pharmaceutical Co., LTD
Status
NOT_YET_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Type 2 Diabetes (T2DM)
Start date
2025-08-01
Primary completion
2028-08-01
Enrollment
496

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.